Stifel Nicolaus Boosts Knight Therapeutics (TSE:GUD) Price Target to C$7.45

Knight Therapeutics (TSE:GUD) had its price target boosted by equities researchers at Stifel Nicolaus from C$6.25 to C$7.45 in a note issued to investors on Tuesday,BayStreet.CA reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ price objective suggests a potential upside of 23.34% from the stock’s previous close.

A number of other research firms have also commented on GUD. Research Capitl upgraded shares of Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 11th. Canaccord Genuity Group downgraded shares of Knight Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 21st. One analyst has rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of C$7.48.

Knight Therapeutics Stock Up 0.5 %

Shares of TSE:GUD opened at C$6.04 on Tuesday. The company has a debt-to-equity ratio of 7.52, a quick ratio of 1.79 and a current ratio of 3.36. The firm has a market capitalization of C$610.95 million, a PE ratio of -20.16, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50. The firm has a fifty day moving average of C$5.72 and a 200 day moving average of C$5.59. Knight Therapeutics has a 52-week low of C$5.09 and a 52-week high of C$6.45.

Insider Transactions at Knight Therapeutics

In related news, insider Sime Armoyan sold 92,200 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of C$6.15, for a total transaction of C$567,030.00. Insiders have sold 3,143,300 shares of company stock worth $19,733,740 in the last quarter. Company insiders own 45.62% of the company’s stock.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.